Health Condition 1: G890- Central pain syndrome
Conditions
Interventions
Intervention1: Pregabline: 75 mg
BD
Route of Administration-Per Oral
Duration-Followed up for 3 months
Control Intervention1: Carbamazepine: 100 mg
TDS For one week then 200 mg TDS
Route of Administr
Sponsors
None listed
Eligibility
Inclusion criteria
Inclusion criteria: The patients with CVJ anomaly diagnosed on the basis clinical features, confirmed by CT or MRI will be included.
Exclusion criteria
Exclusion criteria: Pregnant mother, children ( < 15 years), patients with history of drug allergy, renal or hepatic failure, malignancy, coexistent stroke, head injury or spinal trauma, major psychiatric illness, on immune or chemotherapy, painful neuropathy due to any cause, and those unwilling for consent will be excluded
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in VAS score by 50% will be considered as improvementTimepoint: 1 and 3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Reduction in allodynia in 2. Quantitative sensory Testing (QST) 3. Side Effect Improvement in sleep Timepoint: 1 and 3 months | — |
Countries
India
Contacts
Public ContactJayantee Kalita
Department of Neurology, SGPGIMS
Outcome results
None listed